Saratin, an inhibitor of von Willebrand factor-dependent platelet adhesion, decreases platelet aggregation and intimal hyperplasia in a rat carotid endarterectomy model
Vascular biology article published in Journal of Vascular Surgery (2001)
Abstract
PURPOSE: Post-carotid endarterectomy, thrombosis, and intimal hyperplasia may be decreased by the inhibition of platelet adhesion and activation. In this study, a novel agent, saratin, was used to inhibit platelet-to-collagen adhesion in a rat carotid endarterectomy model. Saratin is a recombinant protein isolated from the saliva of the medicinal leech Hirudo medicinalis, which is thought to act by binding to collagen, and inhibits von Willebrand factor-collagen interaction under conditions of increased shear and therefore, the adherence and activation of platelets at the vessel wall. Saratin has the advantage of being a nonsystemic, site-specific topical application. METHODS: A rat carotid endarterectomy model was used in which an open technique with arteriotomy and intimectomy was used. Saratin was applied to the endarterectomized surface of the carotid artery before arterial closure. End point measurements included platelet adhesion, thrombosis rate, intimal hyperplasia development, bleeding times, and platelet counts. Electron micrographs of carotid arteries were used for quantitative analysis of platelet aggregation and platelet counts. Intimal hyperplasia and thrombosis were assessed with computer-assisted morphometric analysis of elastin-stained carotid artery sections with direct measurement of the intimal hyperplasia area. RESULTS: The topical application of saratin significantly decreased platelet adhesion compared with controls at 3 hours after carotid endarterectomy (64 +/- 17 vs 155 +/- 33 platelets per grid, P = .05), and 24 hours after carotid endarterectomy (35 +/- 11 vs 149 +/- 37 platelets per grid, P = .0110), respectively. A percent luminal stenosis, as a measure of intimal hyperplasia, was significantly decreased with saratin application compared with controls (10.9% +/- 1.8% vs 29.8% +/- 6.8%, P = .0042). This decrease in intimal hyperplasia formation correlated with the inhibition of platelet adhesion. Thirty-three percent of control arteries were found to be thrombosed 2 weeks after carotid endarterectomy compared with a 0% thrombosis rate in the saratin-treated group (P = .0156). No increased bleeding was encountered along the arterial suture line in the saratin group. Bleeding times and systemic platelet counts were not found to change significantly in the saratin-treated rats compared with control rats at 3 and 24 hours after endarterectomy. CONCLUSION: Saratin significantly decreased platelet adhesion, intimal hyperplasia, luminal stenosis, and thrombosis after carotid endarterectomy in rats. Saratin did not increase suture line bleeding or bleeding times, and did not decrease platelet counts. Saratin may serve as a topical agent to be used for the site-specific inhibition of thrombosis and intimal hyperplasia after vascular manipulation.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Zusammenfassung
Topical saratin application after rat carotid endarterectomy significantly decreased platelet adhesion, intimal hyperplasia (10.9% vs 29.8%), and thrombosis (0% vs 33%) without increasing bleeding times or systemic platelet effects.
Warum dies für die Hirudotherapie relevant ist
Diese Studie untersuchte topisch appliziertes rekombinantes Saratin – ein aus dem Speichel von Hirudo medicinalis isoliertes Protein, das Kollagen bindet und die vWF-Kollagen-Interaktion hemmt – in einem Ratten-Karotisendarteriektomie-Modell und maß Thrombozytenadhäsion, Thrombose, Intimahyperplasie, Blutungszeiten und Thrombozytenzahlen. Saratin reduzierte die Thrombozytenadhäsion nach 3 und 24 Stunden signifikant, verringerte die prozentuale Lumenstenose (ein Maß für die Intimahyperplasie), eliminierte die Thrombose nach zwei Wochen gegenüber 33 % in den Kontrollen und verlängerte weder die Blutungszeiten noch senkte es die Thrombozytenzahlen. Dies ist unmittelbar relevant für das Interesse der ASH an antithrombotischen Substanzen aus dem Blutegel-Sekretom und deren stellen-spezifischer Anwendung nach vaskulären Eingriffen. Caveat: Es handelt sich um präklinische Daten aus einem Tiermodell (Ratte) ohne humane Translation; Wirksamkeit und Sicherheit bei Patienten sind nicht belegt.
Zitation
Saratin, an inhibitor of von Willebrand factor-dependent platelet adhesion, decreases platelet aggregation and intimal hyperplasia in a rat carotid endarterectomy model.
Cruz CP, Eidt J, Drouilhet J, Brown AT, Wang Y, Barnes CS, Moursi MM · Journal of vascular surgery, 2001
Verwandter klinischer Kontext
Erfahren Sie, wie diese Forschung mit der klinischen Praxis verknüpft ist
Zur ASH-Bibliothek hinzugefügt: May 26, 2026 · Letzte Aktualisierung der Website: 18. Juni 2026